

# Accepted Manuscript

Long QT Syndrome Type 5-Lite: Defining the Clinical Phenotype Associated with the Potentially Pro-Arrhythmic p.Asp85Asn-KCNE1 Common Genetic Variant

Conor Lane, M.B., B.Ch., John R. Giudicessi, MD, PhD, Dan Ye, MD, David J. Tester, BS, Ram K. Rohatgi, MD, J. Martijn Bos, MD, PhD, Michael J. Ackerman, MD, PhD



PII: S1547-5271(18)30336-9

DOI: [10.1016/j.hrthm.2018.03.038](https://doi.org/10.1016/j.hrthm.2018.03.038)

Reference: HRTM 7541

To appear in: *Heart Rhythm*

Received Date: 3 March 2018

Please cite this article as: Lane C, Giudicessi JR, Ye D, Tester DJ, Rohatgi RK, Bos JM, Ackerman MJ, Long QT Syndrome Type 5-Lite: Defining the Clinical Phenotype Associated with the Potentially Pro-Arrhythmic p.Asp85Asn-KCNE1 Common Genetic Variant, *Heart Rhythm* (2018), doi: 10.1016/j.hrthm.2018.03.038.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Title:** Long QT Syndrome Type 5-Lite: Defining the Clinical Phenotype Associated with the Potentially Pro-Arrhythmic p.Asp85Asn-KCNE1 Common Genetic Variant

**Running Title:** Lane et al. – LQT5-Lite

**Authors:** Conor Lane, M.B., B.Ch.<sup>1\*</sup>, John R. Giudicessi, MD, PhD<sup>2\*</sup>, Dan Ye, MD<sup>1</sup>, David J. Tester, BS<sup>1</sup>, Ram K. Rohatgi, MD<sup>3</sup>, J. Martijn Bos, MD<sup>1</sup>, PhD, and Michael J. Ackerman, MD, PhD<sup>1</sup>

\* These authors contributed equally to this work.

**Institutional affiliations:** <sup>1</sup>Departments of Cardiovascular Medicine (Division of Heart Rhythm Services), Pediatric and Adolescent Medicine (Division of Pediatric Cardiology), and Molecular Pharmacology & Experimental Therapeutics, Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, MN. <sup>2</sup>Departments of Cardiovascular Medicine and Internal Medicine (Clinician-Investigator Training Program), Mayo Clinic, Rochester, MN. <sup>3</sup>Department of Pediatric and Adolescent Medicine (Division of Pediatric Cardiology), Mayo Clinic, Rochester, MN.

**Financial support and conflict of interest disclosure:** Dr. Ackerman is a consultant for Audentes Therapeutics, Boston Scientific, Gilead Sciences, Invitae, Medtronic, MyoKardia, and St. Jude Medical. From 2004 to 2016, M.J.A. and Mayo Clinic received sales-based royalties from Transgenomic for their FAMILION-LQTS and FAMILION-CPVT genetic tests. M.J.A. and Mayo Clinic have potential equity/royalty relationships (without remuneration so far) with AliveCor, Blue Ox Health, and StemoniX. However, none of these entities participated in this study

**Reprints and correspondence:**

Michael J. Ackerman, M.D., Ph.D.  
Mayo Clinic Windland Smith Rice Sudden Death Genomics Laboratory  
Guggenheim 501, Mayo Clinic, Rochester, MN 55905  
507-284-0101 (phone), 507-284-3757 (fax), [ackerman.michael@mayo.edu](mailto:ackerman.michael@mayo.edu)

**Word count of manuscript:** 4,959 words, 3 figures, 1 table, 26 references

**Key Words:** Arrhythmias, Genetics, Long QT Syndrome, LQT5-Lite, Sudden Death

Download English Version:

<https://daneshyari.com/en/article/8660111>

Download Persian Version:

<https://daneshyari.com/article/8660111>

[Daneshyari.com](https://daneshyari.com)